{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:19:19Z","timestamp":1774466359800,"version":"3.50.1"},"reference-count":24,"publisher":"Tech Science Press","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2019,5,7]]},"abstract":"<jats:p>This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients with BCLC stage C liver cancer, after the first cycle of DEB-TACE,\n 2 (5.1%) and 24 (61.5%) patients achieved complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%. With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared with those receiving cTACE (57.1% vs.\n 11.1%). After the first cycle of DEB-TACE treatment, the percentages of abnormal albumin (ALB), total protein (TP), total bilirubin (TBIL), and alanine aminotransferase (ALT) worsened at 1 week and recovered at 1 month. The number of patients with abnormal aspartate aminotransferase (AST)\n did not increase at 1 week but elevated at 1 month. After the second cycle of DEB-TACE or cTACE treatment, no difference was observed between cTACE and DEB-TACE in terms of all adverse events (AEs) at all visits, and most of the AEs did not change after the second cycle in both groups. The\n most common AEs after the first and second treatment cycles were pain, fever, and nausea\/vomiting. These results demonstrate that DEB-TACE offers patients with BCLC stage C liver cancer a clinically active short-term treatment that is safe and relatively well tolerated.<\/jats:p>","DOI":"10.3727\/096504018x15313896322888","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T01:12:03Z","timestamp":1531530723000},"page":"565-573","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and Safety of CalliSpheres<sup>\u00ae<\/sup> Drug-Eluting Beads Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients"],"prefix":"10.32604","volume":"27","author":[{"given":"Yaohong","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wensou","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingji","family":"He","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangshun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","reference":[{"issue":"2","key":"b1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","year":"2015","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"b2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"19","year":"1999","journal-title":"Semin Liver Dis."},{"issue":"4","key":"b3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1515\/raon-2015-0045","article-title":"Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control","volume":"50","year":"2016","journal-title":"Radiol Oncol."},{"issue":"1","key":"b4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clinre.2016.05.013","article-title":"Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis","volume":"41","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"2","key":"b5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s00330-016-4445-9","article-title":"Advanced-stage hepatocellular carcinoma with portal vein thrombosis: Conventional versus drug-eluting beads transcatheter arterial chemoembolization","volume":"27","year":"2017","journal-title":"Eur Radiol."},{"issue":"45","key":"b6","doi-asserted-by":"crossref","first-page":"17206","DOI":"10.3748\/wjg.v20.i45.17206","article-title":"Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: A meta-analysis","volume":"20","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"4","key":"b7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.transproceed.2015.12.078","article-title":"Drug-eluting bead transarterial chemoembolization as bridge therapy for hepatocellular carcinoma before living-donor liver transplantation","volume":"48","year":"2016","journal-title":"Transplant Proc."},{"issue":"6","key":"b8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/hep.26578","article-title":"AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations","volume":"58","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"b9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","year":"2010","journal-title":"Semin Liver Dis."},{"issue":"1","key":"b10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","year":"2009","journal-title":"Lancet Oncol."},{"issue":"4","key":"b11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","year":"2008","journal-title":"N Engl J Med."},{"issue":"1","key":"b12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: The BCLC update and future prospects","volume":"30","year":"2010","journal-title":"Semin Liver Dis."},{"key":"b13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1634\/theoncologist.2010-S4-42","article-title":"Treatment of intermediate\/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved?","volume":"15","year":"2010","journal-title":"Oncologist"},{"issue":"4","key":"b14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00270-010-0044-3","article-title":"Safety profile of sequential transcatheter chemoembolization with DC Bead: Results of 237 hepatocellular carcinoma (HCC) patients","volume":"34","year":"2011","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"7","key":"b15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000329602","article-title":"A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"34","year":"2011","journal-title":"Onkologie"},{"issue":"3","key":"b16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jvir.2009.10.038","article-title":"Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma","volume":"21","year":"2010","journal-title":"J Vasc Interv Radiol."},{"issue":"4","key":"b17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10147-014-0773-4","article-title":"Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: Multicenter phase-II clinical study","volume":"20","year":"2015","journal-title":"Int J Clin Oncol."},{"issue":"2","key":"b18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00270-013-0654-7","article-title":"Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma","volume":"37","year":"2014","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"3","key":"b19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jvir.2012.11.026","article-title":"Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma","volume":"24","year":"2013","journal-title":"J Vasc Interv Radiol."},{"issue":"4","key":"b20","first-page":"437","article-title":"Treatment of unresectable cholangiocarcinoma: Conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy","volume":"24","year":"2012","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"9","key":"b21","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jvir.2016.05.014","article-title":"Conventional versus drug-eluting bead transarterial chemoembolization for neuroendocrine tumor liver metastases","volume":"27","year":"2016","journal-title":"J Vasc Interv Radiol."},{"issue":"1","key":"b22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1148\/radiol.14131946","article-title":"Hepatocellular carcinoma with portal vein tumor thrombus: Treatment with transarterial chemoembolization combined with sorafenib\u2014A retrospective controlled study","volume":"272","year":"2014","journal-title":"Radiology"},{"issue":"12","key":"b23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/hpb.12487","article-title":"Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma","volume":"17","year":"2015","journal-title":"HPB (Oxford)"},{"issue":"30","key":"b24","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","year":"2011","journal-title":"J Clin Oncol."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20220623\/20220623105329_66748.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:37:48Z","timestamp":1733521068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v27n5\/48572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,7]]}},"alternative-id":["0965-0407(20190507)27:5L.565;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504018x15313896322888","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}